Ibtrozi (Taletrectinib) for Lung Cancer

Overview
Ibtrozi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic (advanced) non-small cell lung cancer (NSCLC) that tests positive for ROS1 gene rearrangements. Eligibility for treatment with Ibtrozi requires confirmation of ROS1 rearrangement in the cancer cells. Ibtrozi is also known by its drug name, taletrectinib.

Ibtrozi is a type of targeted therapy called a kinase inhibitor. It works by blocking abnormal ROS1 proteins in cancer cells, which can slow or stop the growth of tumors in people with ROS1-positive NSCLC.

How do I take it?
Prescribing information states that Ibtrozi is taken by mouth as a capsule once daily on an empty stomach. No food should be consumed for at least two hours before and after taking the drug. Treatment continues until the cancer progresses or side effects become unmanageable. Ibtrozi should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Ibtrozi include diarrhea, nausea, vomiting, dizziness, rash, constipation, and fatigue.

Rare but serious side effects may include hepatotoxicity (liver damage), interstitial lung disease or pneumonitis (inflammation of the lungs), QTc interval prolongation (heart rhythm problems), hyperuricemia (high levels of uric acid in the blood), muscle pain with increased muscle enzymes (myalgia with elevated creatine phosphokinase), and bone fractures. Ibtrozi may also harm an unborn baby, so effective birth control is recommended during treatment.

For more information about this treatment, visit:
Prescribing Information: Ibtrozi (Taletrectinib) Capsules, for Oral Use — Nuvation Bio